TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using RenovoCath® as a Stand-Alone Device for Drug-Delivery in Oncology Management MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today ...

Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestonesMOUNTAIN VIEW, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the closing of its previously announced, oversubscribed private placement of common st ...

Core Viewpoint - RenovoRx, Inc. is set to announce its fourth quarter and full year 2025 financial results and business highlights on March 30, 2026, showcasing its progress in oncology therapies and the commercialization of its FDA-cleared drug-delivery device, RenovoCath [1][4]. Group 1: Financial Results and Conference Call - The conference call will take place on March 30, 2026, at 4:30 p.m. ET, where management will discuss financial results and business highlights [1][4]. - A recording of the call will be available on the Investor Relations website, with a dial-in replay accessible until April 13, 2026 [4]. Group 2: Clinical Pipeline and Product Development - Management will provide updates on the clinical pipeline, particularly the Phase III TIGeR-PaC trial for locally advanced pancreatic cancer, which is on track for enrollment completion in the first half of 2026, with final data expected in 2027 [3]. - The company is focusing on generating new data through post-marketing registry studies and supporting investigator-initiated trials (IIT) in pancreatic cancer, which are designed to be cost-neutral and provide meaningful data for the TAMP™ therapy platform [3]. Group 3: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and RenovoCath, having received its first commercial purchase orders in December 2024, generating approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025 [6]. - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [6]. Group 4: Product Candidates and Regulatory Status - RenovoRx is evaluating its intra-arterial gemcitabine product candidate delivered via RenovoCath in the ongoing Phase III TIGeR-PaC trial, which is regulated under a U.S. investigational new drug application [7]. - The IAG combination product candidate has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8].

Core Viewpoint - RenovoRx, Inc. has successfully executed an oversubscribed private placement expected to generate approximately $10 million in gross proceeds, aimed at accelerating its commercialization efforts and advancing clinical trials for its innovative oncology therapies [1][3][6] Financing Details - The financing is led by prominent life-science institutional investors, with participation from the company's senior management and board members [2] - The private placement will involve the issuance of approximately 10,638,869 shares of common stock at a purchase price of $0.938 per share, along with milestone-based warrants for an additional 5,319,434 shares [4][5] Use of Proceeds - Proceeds from the financing are intended to support RenovoRx's commercialization of RenovoCath and to advance the pivotal Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer, targeting full enrollment by mid-2026 [3][12] - The company aims to achieve cash-flow breakeven operations while reducing cash burn and increasing revenue [3] Warrant Details - The milestone warrants have an exercise price of $1.751 per share, representing a 100% premium to the common stock offering price, and are exercisable immediately [5] - The warrants will expire either 30 days after the company announces achieving $1.5 million in gross product revenue or on March 30, 2029 [5] Company Overview - RenovoRx is focused on developing targeted oncology therapies and commercializing RenovoCath, a patented FDA-cleared drug-delivery device designed for localized treatment [11][12] - The company has generated approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025, with repeat orders from several customers [12]

Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences comp ...

Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic CancerMOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract s ...

Core Insights - RenovoRx has established a Medical Advisory Board (MAB) to enhance its TAMP™ therapy platform, focusing on clinical indications with high unmet medical needs [1][2][5] Group 1: Medical Advisory Board Formation - The MAB consists of leading US interventional radiology experts who will provide strategic clinical insights to advance the TAMP therapy platform [2][3] - The MAB will complement the existing Scientific Advisory Board, which focuses on scientific research and clinical program strategy [2] Group 2: Clinical and Market Strategy - The MAB will support ongoing clinical and market strategies and provide insights into potential investigator-initiated trials, which are designed to broaden the application of the TAMP platform [3] - Current trials supported by RenovoRx include studies on borderline resectable and metastatic pancreatic cancer, with potential for expanding targeted indications [3] Group 3: Feedback and Market Introduction - The MAB will also provide feedback to the sales and marketing team as they work to bring RenovoCath to market as a standalone device within its FDA-cleared indications [4] Group 4: RenovoCath Overview - RenovoCath is an FDA-cleared drug-delivery device intended for targeted therapeutic delivery across the arterial wall near tumor sites, aiming to minimize toxicities compared to systemic intravenous therapy [12][13] - The device is also indicated for temporary vessel occlusion in various applications, including arteriography and chemotherapeutic drug infusion [12] Group 5: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices, generating approximately $900,000 in revenue for the first nine months of 2025 [14] - The company is actively exploring further revenue-generating activities to meet anticipated demand [14] Group 6: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [15][16] - IAG has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [17]

Core Viewpoint - RenovoRx has appointed Mark Voll as Chief Financial Officer to enhance its leadership team and support the commercialization of its RenovoCath drug-delivery device, marking a significant transition from a clinical stage to a commercial company [1][4]. Group 1: Appointment and Leadership - Mark Voll brings over 30 years of financial leadership experience, having successfully guided high-growth public companies through commercial development [2]. - Voll's role will focus on stockholder communications, budgeting, strategic planning, and finance, which are crucial as RenovoRx commercializes RenovoCath and advances its Phase III TIGeR-PaC clinical trial [3][4]. - CEO Shaun Bagai expressed confidence in Voll's ability to drive sustained commercial execution during this pivotal time for the company [4]. Group 2: Company Overview and Product Information - RenovoRx is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device designed for targeted therapeutic delivery [7]. - RenovoCath is intended for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications including arteriography and chemotherapeutic drug infusion [6]. - The company has begun commercializing the TAMP therapy platform and RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8]. Group 3: Clinical Trials and Future Prospects - RenovoRx is evaluating a novel drug-device combination candidate, IAG, in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9][10]. - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10].

Core Insights - RenovoRx, Inc. is advancing its innovative targeted oncology therapies through the RenovoCath device, which has received FDA clearance for drug delivery [1][7] - New clinical data will be presented at the 2026 Society of Interventional Oncology Annual Scientific Meeting, focusing on optimizing drug delivery in solid tumors using the TAMP therapy platform [1][2] Clinical Study Findings - The study titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" aims to simplify intra-arterial pressure measurement during TAMP procedures [2][4] - Real-time pressure measurements provide insights into the mechanics of TAMP procedures, potentially enhancing drug delivery effectiveness [3][4] - The study demonstrates that an external pressure transducer can reliably measure intra-arterial pressure, correlating well with intravascular pressure wire measurements [3] Presentation Details - The clinical data will be presented on February 6, 2026, at 5:45-6:00 PM ET, with the abstract number 303 [4] Company Overview - RenovoRx is focused on developing targeted therapies for high unmet medical needs, utilizing the TAMP therapy platform to minimize toxicities compared to systemic therapies [7] - The company is in the early stages of commercializing the RenovoCath device, having generated approximately $900,000 in revenue from sales in the first nine months of 2025 [8] Product Development - RenovoRx is evaluating a novel drug-device combination candidate, IAG, which involves intra-arterial delivery of gemcitabine via RenovoCath, currently in Phase III trials [9][10] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, granting seven years of market exclusivity upon FDA approval [10]

Core Insights - RenovoRx, Inc. announced the acceptance of its abstract submission for the 2026 Society of Interventional Oncology Annual Scientific Meeting, highlighting its innovative targeted oncology therapies and the RenovoCath drug-delivery device [1][6] Group 1: Clinical Study Presentation - The clinical data abstract titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" will be presented by researchers including Dr. Christopher Laing [2] - The study aims to validate a real-time method for intra-arterial pressure monitoring during TAMP procedures using the RenovoCath device, potentially optimizing chemotherapy delivery in challenging tumors [4] Group 2: RenovoCath Overview - RenovoCath is FDA-cleared for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications in arteriography, preoperative occlusion, and chemotherapeutic drug infusion [5][7] - The device is part of RenovoRx's TAMP therapy platform, designed to enhance targeted therapeutic delivery while minimizing toxicities compared to systemic intravenous therapy [7] Group 3: Commercialization and Financials - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8] - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [8] Group 4: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10]